Compare H2O America (HTO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? H2O America trades at $57.11 (market cap $2.45B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: H2O America is far larger — about 2.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and H2O America pays a 3.01% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 39 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HTO | MRVI | |
|---|---|---|
Market Cap | $2.45B | $972.90M |
Volume | 419,336 | 4,325,710 |
Sector | Utilities | Health |
52-Week High | $65.43 | $9.00 |
52-Week Low | $44.44 | $2.83 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $4.24B | $1.08B |
Dividend Yield | 3.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.49, down 0.27% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with 12.91% net income margin and consistent earnings beats in recent quarters. Recent acquisitions in Texas expand operations but require significant capital investment. Cash flow trends improved from $10M in 2025 to $84M in 2026, supporting dividend sustainability.
Outlook remains positive with 83% analyst buy ratings and $66.50 consensus target offering 14% upside. Key risks include acquisition integration and execution challenges. The stock presents value for income investors given Dividend King status and strategic growth initiatives in regulated water utilities.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
